GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Recurrent Glioblastoma

Interventions

DRUG

GX-I7

Administered by intramuscular (IM) injection

DRUG

Bevacizumab

Administered by intravenous (IV) injection

Trial Locations (1)

Seoul St.Mary's Hospital of the Catholic University of Korea, Seoul